Beijing Beilu Pharmaceutical Co Ltd
SZSE:300016
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Beijing Beilu Pharmaceutical Co Ltd
SZSE:300016
|
CN |
|
M
|
Milux Corporation Bhd
KLSE:MILUX
|
MY |
|
Helios Underwriting PLC
LSE:HUW
|
UK |
|
ICICI Lombard General Insurance Company Ltd
NSE:ICICIGI
|
IN |
|
N
|
Nexen Corp
KRX:005720
|
KR |
|
S
|
Salutica Bhd
KLSE:SALUTE
|
MY |
|
S
|
Shanghai Guangdian Electric Group Co Ltd
SSE:601616
|
CN |
|
Shanghai Fengyuzhu Culture Technology Co Ltd
SSE:603466
|
CN |
|
K
|
Kinetic Development Group Ltd
HKEX:1277
|
CN |
|
Z
|
Zhejiang Langdi Group Co Ltd
SSE:603726
|
CN |
|
A
|
AIT Corp
TSE:9381
|
JP |
|
InTiCa Systems AG
XETRA:IS7
|
DE |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Beijing Beilu Pharmaceutical Co Ltd's stock price target?
Not Available
Beijing Beilu Pharmaceutical Co Ltd doesn't have any price targets made by Wall Street professionals.
What is Beijing Beilu Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
1%
For the last 13 years the compound annual growth rate for Beijing Beilu Pharmaceutical Co Ltd's revenue is 13%. The projected CAGR for the next 4 years is 1%.
What is Beijing Beilu Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
12%
For the last 13 years the compound annual growth rate for Beijing Beilu Pharmaceutical Co Ltd's operating income is 2%. The projected CAGR for the next 9 years is 12%.
What is Beijing Beilu Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
106%
For the last 13 years the compound annual growth rate for Beijing Beilu Pharmaceutical Co Ltd's net income is -9%. The projected CAGR for the next 4 years is 106%.
